

Impact on physical fitness and cognitive ability in school children from southern Côte d'Ivoire after treatment against intestinal helminth infections

Submission date 25/10/2012	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 19/11/2012	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 14/05/2015	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Millions of people in the developing world are at risk of parasitic diseases such as malaria and the so-called neglected tropical diseases (NTDs). The latter include, among others, parasitic worm (helminth) infections, such as soil-transmitted helminthiasis and schistosomiasis. There is a lack of studies investigating the effects of infection with multiple parasites (polyparasitism). Due to the long-lasting and un-specific nature of the symptoms, the public health burden can be greatly underestimated. Given that helminth and schistosomiasis infections cause malnutrition and anemia in school-aged children, it is also possible that they reduce their physical fitness, strength and school performance. The main aims of this study is to determine whether polyparasitic infections including soil-transmitted helminths and schistosomiasis have negative consequences on the physical fitness, strength and cognitive abilities of school-aged children in south-central Côte d'Ivoire, and if treatment against these diseases improves performance in infected children.

Who can participate?

All primary school children from grade 3-6 (age range: 8-15 years) will be invited to participate in this study.

What does the study involve?

The children will submit a stool, urine and finger-prick blood sample, and complete physical and cognitive tests and clinical examinations. All study participants will be treated against soil-transmitted helminths and schistosomiasis with a single dose of albendazole and praziquantel at the start of the study and 2 months and 5 months later. Further tests will take place at the end of the study follow-up, 7 months after the start of the study.

What are the possible benefits and risks of participating?

All participating children will benefit from repeated de-worming with albendazole and praziquantel free of charge. Both treatments are shown to be highly effective against the

common soil-transmitted helminths and schistosomiasis, respectively, and have good safety profiles. Treatment will also be offered for children with malaria or severely anaemia.

Where is the study run from?

The study will be conducted in a rural primary school in Agboville department, Agnéby region, Côte d'Ivoire.

When is the study starting and how long is it expected to run for?

The study will start in November 2012 and will run for about 7 months.

Who is funding the study?

Swiss National Science Foundation (SNSF).

Who is the main contact?

Prof. Dr Jürg Utzinger

juerg.utzinger@unibas.ch

Contact information

Type(s)

Scientific

Contact name

Prof Juerg Utzinger

Contact details

Swiss Tropical and Public Health Institute

Socinstrasse 57

Basel

Switzerland

4002

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Impact on physical fitness and cognitive ability in school children from southern Côte d'Ivoire after treatment against soil-transmitted helminths and schistosomiasis

Study objectives

Treatment against soil-transmitted helminths and schistosomiasis can improve the physical fitness, strength and school performance of school-aged children.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Ethikkommission beider Basel, Switzerland, 14/04/2011, ref: 30/11 (amendment, 21/06/2011)
2. Comité National d'Ethique et de la Recherche, Côte d'Ivoire, 03/01/2011, ref: 09-2011/MSHP/CNER-P

Study design

Intervention study with cross-sectional assessment

Primary study design

Interventional

Secondary study design

Cross-section survey

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Neglected tropical diseases (soil-transmitted helminth and schistosomiasis infections) and malaria

Interventions

All participants of the study will be treated against soil-transmitted helminths and schistosomiasis with a single dose of albendazole (400 mg) and praziquantel (40 mg/kg), respectively, at baseline, 2 month, 5 months and 7 months (follow-up assessment) after launch of the study.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Albendazole, praziquantel

Primary outcome measure

Differences (non-infected vs. infected) and changes (before and after treatment) in physical fitness, strength and cognitive ability

Secondary outcome measures

1. Reduction of infection prevalence and intensity of soil-transmitted helminths and schistosomiasis
2. Differences and changes in disease-related morbidity measures (malnutrition, anemia, organomegaly)

Overall study start date

01/11/2012

Completion date

01/06/2013

Eligibility

Key inclusion criteria

1. Primary school child, aged 8-15 years, male or female
2. Written informed consent by a parent/guardian on behalf of the child
3. Submission of 1 urine, 1 stool and 1 finger-prick blood sample at baseline
4. Completion of clinical, anthropometric and haemoglobin measurements at baseline
5. Completion of 20 m shuttle run test at baseline
6. Completion of grip strength test and standing broad jump test at baseline
7. Completion of cognitive testing
8. Absence of difficult health condition (clinical malaria, severe anemia, respiratory disease or other major illnesses) as assessed by a medical doctor at baseline
9. No known or reported drug allergy to albendazole or praziquantel
10. Treatment with albendazole and praziquantel

Participant type(s)

Patient

Age group

Child

Lower age limit

8 Years

Upper age limit

15 Years

Sex

Both

Target number of participants

Approximately 300

Key exclusion criteria

1. Children below the age of 8 years or above 15 years
2. No written informed consent
3. No complete set of urine, stool and blood sample submitted at baseline
4. Presence of medical condition that prevents child from completing the physical fitness and strength tests
5. Known or reported drug allergy to albendazole or praziquantel
6. Absence/refusal of albendazole and/or praziquantel treatment
7. Attending other clinical trials during the study period

Date of first enrolment

01/11/2012

Date of final enrolment

01/06/2013

Locations

Countries of recruitment

Côte d'Ivoire

Switzerland

Study participating centre

Swiss Tropical and Public Health Institute

Basel

Switzerland

4002

Sponsor information

Organisation

Swiss Tropical and Public Health Institute (Switzerland)

Sponsor details

Socinstrasse 57

Basel

Switzerland

4002

Sponsor type

Research organisation

Website

<http://www.swisstph.ch/>

ROR

<https://ror.org/03adhka07>

Funder(s)

Funder type

Government

Funder Name

Swiss National Science Foundation [SNSF] (Switzerland)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration